Pancreatic Cancer Research

ResearcherShikoku Cancer CenterActive in the last 2 years

Akinori Asagi

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5029308875. Sources: OpenAlex.

Their work

Papers
12
Trials
0
Grants
0
Labs led
0
Collaborators
59
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: 3 papers · 2023: none · 2024: 1 paper · 2025: 5 papers

Papers 12

  1. Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of trea… Co-author DOI 10.1007/s00535-024-02186-9↗
  2. Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probabi… Co-author DOI 10.1007/s00535-025-02215-1↗
  3. A multicenter prospective observational study for health assessment questionnaires EQ-5D-5L and G8 in unresectable advanced pancreatic cancer treated with firs… Co-author DOI 10.1007/s10147-025-02717-1↗
  4. Clinicopathological features for clinically resectable peripherally located pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2025.06.010↗
  5. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  6. Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer. Co-author DOI 10.1038/s41416-024-02834-0↗
  7. Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial … Co-author DOI 10.1093/jjco/hyab194↗
  8. Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.8736-21↗
  9. Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study. Co-author DOI 10.21873/anticanres.15547↗
  10. Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovaria… Co-author DOI 10.1007/s10147-020-01721-x↗
  11. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and de… Co-author DOI 10.1097/mpa.0b013e3182550d77↗
  12. [Gemcitabine plus S-1 combination therapy (GS therapy) for pancreatic cancer patients with high-grade hepatic metastasis]. Co-author PMID 22139487↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masafumi Ikeda · 5 shared papers, 2020–2025 · strength 0.67
  2. Naohiro Okano · 5 shared papers, 2020–2025 · strength 0.67
  3. Makoto Ueno · 5 shared papers, 2020–2025 · strength 0.67
  4. Chigusa Morizane · 5 shared papers, 2020–2025 · strength 0.67
  5. Junji Furuse · 5 shared papers, 2020–2025 · strength 0.64
  6. Yasuyuki Kawamoto · 4 shared papers, 2022–2025 · strength 0.59
  7. Mitsuhito Koizumi · 3 shared papers, 2022–2025 · strength 0.56
  8. Ichinosuke Hyodo · 3 shared papers, 2022–2025 · strength 0.56
  9. Yoichi Hiasa · 3 shared papers, 2022–2025 · strength 0.56
  10. Hiroaki Nagano · 4 shared papers, 2022–2025 · strength 0.56
  11. Yoshinori Ohno · 3 shared papers, 2022–2025 · strength 0.55
  12. Kunihiro Tsuji · 4 shared papers, 2020–2025 · strength 0.51
  13. Kumiko Umemoto · 3 shared papers, 2024–2025 · strength 0.48
  14. Nobumasa Mizuno · 4 shared papers, 2020–2024 · strength 0.47
  15. Toru Otsuru · 2 shared papers, 2025 · strength 0.45
  16. Satoshi Kobayashi · 3 shared papers, 2022–2025 · strength 0.43
  17. Rei Suzuki · 3 shared papers, 2022–2025 · strength 0.43
  18. Yohei Kitano · 2 shared papers, 2025 · strength 0.32
  19. Nana Kimura · 2 shared papers, 2025 · strength 0.32
  20. Takeshi Terashima · 2 shared papers, 2025 · strength 0.32
  21. Masayuki Ueno · 2 shared papers, 2025 · strength 0.32
  22. Toshifumi Doi · 2 shared papers, 2025 · strength 0.32
  23. Reiko Ashida · 2 shared papers, 2025 · strength 0.32
  24. Kohei Nakachi · 2 shared papers, 2025 · strength 0.32
  25. Akihiro Ohba · 2 shared papers, 2025 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.